The FDA's oncologic drugs advisory committee (ODAC) voted 13 to 1 against the approval of Taltorvic (ridaforolimus) by Ariad Pharmaceuticals Inc., partnered with Merck & Co. Inc., for soft-tissue and bone sarcoma.